Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need.
A Bold, Scientific Approach to the Discovery & Development of Innovative Medicines
The discovery of a new medicine is a complex journey of innovation, determination, and insight where both biology and chemistry orchestrate a potential solution for patients. At Prelude Therapeutics, we go where the science leads us, not constrained within a platform, or by a specific target class or chemical modality, to solve challenging, unmet needs of patients. We strive to turn our scientific insights into safe and effective drugs to improve the lives of people with cancer.
Take a look at what we have achieved and how we were able to do it »
CDK9 is a cyclin dependent kinase and an essential regulator of cancer-promoting transcriptional programs
Potentially Best-in-Class Selectivity
Potential to avoid off-target toxicity and higher clinical activity
CDK9
Precision
ADCs
CDK4/6
SMARCA2
CDK9 is a cyclin dependent kinase and an essential regulator of cancer-promoting transcriptional programs
Potentially Best-in-Class Selectivity
Potential to avoid off-target toxicity and higher clinical activity
Prelude and its partner AbCellera to develop potent degraders/inhibitors as payloads for novel antibodies targeting tumor specific antigens
Next generation ADCs to extend the therapeutic utility of this class.
CDK4 and CDK6 play a central role in cell cycle regulation, dysregulation of the CDK4/CDK6 pathway as potential therapeutic targets for cancer treatment
Highly Selective CDK4 Bias
Potential for high tissue and brain penetration and better combinability
SMARCA2 protein degraders designed to be synthetic lethal to SMARCA4 deletion that occur in a wide range of cancers
Potent and Selective Degrader
Potential to address major unmet need in biomarker-selected patients
Our Clinical Trials
Innovations in research and discovery, improved technologies, a deeper understanding of cancer biology and behavior, and novel scientific approaches are providing new hope for patients. The Prelude team is proud to have advanced several transformational cancer therapies for patients and we are rapidly moving additional novel therapeutics into clinical trials.
Our Team
With multiple, diverse first/best-in-class programs already in the clinic, we feel the urgency of applying our team’s expertise to finding the therapies that transform patients’ lives. Our cause is cancer, our purpose is patients, and we strive to develop safe, effective, and durable treatments to help improve patients’ lives.
Press Releases
September 13, 2024
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
September 9, 2024
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
August 12, 2024
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Highly Selective SMARCA2 Degraders
Educational Video Series